)
)
)
Resolution Therapeutics
Resolution Therapeutics is a clinical stage pioneer in Regenerative Macrophage Therapies (RMT) for Inflammatory and Fibrotic Diseases. CLINICAL PROGRAM / HIGH UNMET NEED - EMERALD/OPAL (P1/2) for End Stage Liver Disease (ESLD), which affects >500k people in the US with liver transplantation as the only option, leaving over 90% of patients with no alternative. TRANSFORMATIVE TREATMENT - Engineered macrophages with enhanced anti-inflammatory and anti-fibrotic efficacy, optimised by payload ROBUST SCIENCE & CLINICAL EVIDENCE - Two clinical Proof of Concept studies demonstrating safety and efficacy in patients with cirrhosis; robust biomarker package FOCUSED PIPELINE - Efficacy demonstrated in lung fibrosis and GvHD with platform expansion into In Vivo modality
What is your next catalyst (value inflection) update?
EMERALD/OPAL - Interim data readout
Year Founded
2020
Lead Product in Development
EMERALD/OPAL - RTX001 for decompensated cirrhosis
Development Phase of Lead Product
Phase II
CEO/Top Company Official
Dr Amir Hefni
When you expect your next catalyst update?
July 2026
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
